244 results about "Chronic infection" patented technology

The present invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof. The present invention further provides methods for treating various cancers and chronic infections with stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof.

The present invention relates to methods of making and using chimeric antibody molecules comprised of at least two domains, namely R_AF, and I_AF, linked by a flexible peptide linker.

Compositions and methods useful for modulating immunity, enhancing vaccine efficacy, decreasing morbidity associated with chronic FHV-1 infections, and/or preventing or treating conjunctivitis in animals. The compositions contain effective amounts of probiotic Enterococcus bacteria and the methods involve administering such compositions to animals alone, in supplements, or in food compositions in amounts suitable for the intended purpose. In certain embodiments, the probiotic is Enterococcus faecium strain NCIMB 10415 (SF68) and the animal is a feline.

The invention concerns a gene therapy for treatment of animals and humans which suffer from an infection with a chronic virus such as HIV or HCV. It can also be used prophylactically to prevent chronic infection. The therapy makes use of a nucleotide construct stably integrated in the genome of the target cells of the virus, which is able to produce a single transcript or multiple transcripts capable of forming a double-stranded RNA which inhibits replication of the virus in situ.

The invention is for the combination of EDTA, cystine, selenium, Vitamin C, Vitamin E, and zinc for anti-thrombotic effect and for the effect of restoring platelet aggregation, an integral component of thrombus formation, to normal and for the monitoring of the response to therapy with the combination. Methods for use of the components and method for performing the monitoring are included. The combination and method are particularly efficacious for vascular deficiency ailments including atherosclerotic vascular disease, reduction of ischemic cerebal event, complications from surgical procedures including restenosis, neurogenerative disease, and erectile disfunction, and vascular deficiency resulting from etiology of sepsis and chronic infection.

A convenient way of inducing a broad recognition of dominant and subdominant responses to epitopes of any given antigen of importance for prophylaxis or treatment of a chronic disease is provided. The method involves by immunizing with pools of overlapping fragments (synthetic peptides, e.g., 10-30 mers with 2-20 aa overlap) of the desired antigen in appropriate adjuvants. The T cell repertoire is primed to include not only the immunodominant epitope recognized when the intact molecule is used for immunization and induced by the chronic infection itself, but induce a much broader and balanced response to a number of the subdominant epitopes as well. The vaccination with peptide mix induces a T-cell response that includes response to subdominant epitopes is important for protection against chronic disease that on their own induces a response focused only on immunodominant epitopes. The major advantage of the present invention is that it requires no prior knowledge of the precise localisation and identity of the subdominant epitopes and their recognition in a human population, but expands the T-cell repertoire and thereby the total number of epitopes recognized by specific T cells primed by vaccination from a few immunodominant epitopes to a multiple of epitopes.

The invention relates to a silver thiosulfate complex or silver-ammonia complex-containing hygroscopic silver-containing product and a preparation method thereof. The invention discloses a hygroscopic silver-containing antibacterial product which comprises a silver thiosulfate complex or a silver-ammonia complex as an antibacterial ingredient, the silver thiosulfate complex or the silver-ammonia complex is evenly distributed and combined on the inner side and / or surface, the hygroscopic silver-containing antibacterial product comprises 0.01-10 wt% of silver, and the moisture absorption ability of the hygroscopic silver-containing antibacterial product is 6g/ g and above. The invention also provides a preparation method of the hygroscopic silver-containing antibacterial product as well as a silver-containing antibacterial product dressing prepared from the hygroscopic silver-containing antibacterial product. The hygroscopic silver-containing antibacterial product has a very wide antibacterial spectrum, shows strong antibacterial activity to gram-negative bacteria and gram-positive bacteria, is rapid in effect, has light stability, and can be widely applied to chronic infections exudative wounds.

Methods and devices for the detection of proteins secreted by the pathogenic growth form of Candida species are disclosed. The disclosed devices may constitute a method for the diagnosis of acute or chronic infections, including candidiasis, caused by microorganisms of the Candida species, such as C. albicans, for example. The devices of the present invention incorporate antibodies specific to lipase proteins whose expression is differentiated upon the conversion of the Candida species from the commensal to the pathogenic form. The antibodies may be used in assays to allow the diagnosis of candidal infections and disease conditions. Either monoclonal antibodies or polyclonal antibodies may be used, and in the case of the monoclonals, the specific epitopes of the LIP protein may be detected as well as the LIP protein itself.

The invention concerns compositions comprising a demethylationg agent and an antigen for inducing and enhancing antigen-specific immunity and uses thereof. The invention also concerns methods for enhancing antigen-specific immunity by administrating a demethylating agent.

The present invention provides methods or kits with inflammatory cytokines to pretreat 1-ISCs to augment their immune modulatory effect, in prevention and treatment of various diseases such as multiple sclerosis, arthritis, lupus, sepsis, hepatitis, cirrhosis, Parkinson's disease, chronic infections, and GvHD. The present invention relates to novel methods for enhancing the immunosuppressive or the immune stimulatory activities of mesenchymal stem cells (JvfSCs).

The invention discloses liquid dressing capable of sterilizing and repairing wounds and a production method of the liquid dressing. The liquid dressing is double-emulsion-system solution using water-soluble amino polysaccharide, sterilizing preservatives and high-molecular polymer as main active constituents and high-molecular emulsifier as the emulsifier. The liquid dressing has the advantages that the liquid dressing can promote wound healing, resist exudation, inhibit bacteria and prevent infection and is applicable to washing or wet dressing treatment of related wounds such as scald wounds, knife wounds and chronic infection wounds. The production method of the liquid dressing includes: preparing water-soluble amino polysaccharide emulsion solution, preparing antibacterial compound emulsion solution, compounding a double-emulsion system and sterilizing.

New markers for diseased liver conditions have been identified. A combination of protein C (PROC) and retinol binding protein 4 (RBP4) in blood are biomarkers to distinguish patients at different stages of hepatic fibrosis due, for example, to chronic infection with hepatitis C virus (HCV). Also, alpha-1-B glycoprotein (A1BG), complement factor H (CFH) and insulin-like growth factor binding protein acid labile subunit (IGFALS) distinguish subjects with chronic or acute liver conditions such as hepatitis infection or liver fibrosis from healthy controls.

The invention discloses a replicative HBV (Hepatitis B Virus) vector carrying a foreign gene and a recombinant HBV generated after transfection and a corresponding preparation method and an application. The vector separates overlaying genes C and P on an HBV genome by a molecular cloning technique based on originally expressed HBV plasmid to respectively form an integral opened reading frame where a protein translation starting sequence or a protease enzyme cutting site is inserted to respectively guide expression of foreign gene and gene P. The replicative HBV vector carrying the foreign gene transiently transfecting hepatoma carcinoma cell secretes the recombinant HBV. The recombinant HBV prepared from the HBV vector transfection cells provided by the invention can express the foreign gene and maintain the replicative and infecting capacity. The invention is suitable for constructing an HBV chronic infection animal model, an HBV cell model with cccDNA stably and automatically replicated and a traceable HBV strain, researching a molecular mechanism of HBV infection, replication, packaging and the like, and screening anti-HBV novel medicines.

The invention discloses application of RNA and carrier in preparation of a product for preventing and/or treating liver cancer. The invention provides a recombinant adenovirus carrier which is a recombinant adenovirus carrier formed by inserting at least one encoding gene of miR-122 into a pDC312-cmv; and the miR-122 refers to RNA shown in a sequence 1 in a sequence table or RNA encoded by a sequence 3 in the sequence table. The experiment proves that the miR-122 encoding genes are introduced into the adenovirus carrier, the adenovirus is purified and is used for performing an animal experiment, the miR-122 and the recombinant adenovirus carrier or adenovirus can obviously suppress the liver cancer caused by chronic hepatitis B infection, and a novel liver cancer treatment medicine can be developed.

The present invention is directed to LAK-T cells, which have been transformed by a transgenic T cell receptor (tg-TCR). The invention is further directed to a method of generating those transgenic T cells, a pharmaceutical composition comprising said cells and the use of the LAK-T cells or of the pharmaceutical composition in the adoptive cell therapy and for treating hematological malignancies or solid tumors or acute or chronic infections or autoimmune diseases.

Methods and compositions are provided for inducing phagocytosis of a target cell, treating an individual having cancer, treating an individual having an intracellular pathogen infection (e.g., a chronic infection), and/or reducing the number of inflicted cells (e.g., cancer cells, cells infected with an intracellular pathogen, etc.) in an individual. Methods and compositions are also provided for predicting whether an individual is resistant (or susceptible) to treatment with an anti-CD47/SIRPA agent. In some cases, the subject methods and compositions include an anti-MHC Class I/LILRB1 agent. In some cases, the subject methods and compositions include an anti-MHC Class I/LILRB1 agent and an anti-CD47/SIRPA agent (e.g., co-administration of an anti-MHC Class I/LILRB1 agent and an anti-CD47/SIRPA agent). Kits are also provided for practicing the methods of the disclosure.

The present invention relates to combination of one or more SGLT2 inhibitors or pharmaceutically acceptable forms and/or salts thereof and one or more dopamine receptor agonists or pharmaceutically acceptable forms and/or salts thereof, preferably in the treatment and/or prevention of a metabolic disorder of an equine animal, wherein more preferably the metabolic disorder is one or more disorders selected from Equine Metabolic Syndrome (EMS), Equine Pituitary Pars Intermedia Dysfunction (PPID), also known as equine Cushing's syndrome, laminitis, vascular dysfunction, hypertension, hepatic lipidosis, hyperadreeocorticism, glucose intolerance, insulin resistance, hyperinsulinaemia, hirsutism, hyperhidrosis. polyuria, polydipsia, chronic infections, abnormal fat distribution, muscle wasting, abnormal weight loss and/or loss of appetite.